SEC62 and prostate carcinoma: Correlations of IHC-detected SEC62 overexpression with poor clinical outcomes (i.e., reduced PFS and OS) have been reported for ovarian, non-small cell lung, head and neck, hepatocellular, and prostate cancers, with sample sizes ranging from 22 to 167 patients [9,14,16,24,25].